Martin De Hann

Title: Martin De Hann: Innovator in Pharmaceutical Chemistry

Introduction

Martin De Hann is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various neurological and psychological disorders. His work is characterized by a commitment to improving therapeutic outcomes for patients suffering from a range of conditions.

Latest Patents

Martin De Hann holds a patent concerning arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors. This invention includes methods for the preparation of these compounds and novel intermediates useful for their synthesis. The patent outlines the therapeutic uses of these compounds, which are aimed at treating conditions such as Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, and many others. The compounds have a general formula that is detailed in the patent description.

Career Highlights

Martin De Hann is currently associated with AbbVie Bahamas Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the understanding and treatment of complex disorders, showcasing his expertise and dedication to improving patient care.

Collaborations

Some of Martin's notable coworkers include Arnold Van Loevezijn and Wouter I Iwema Bakker. Their collaborative efforts contribute to the innovative environment at AbbVie Bahamas Limited, fostering advancements in pharmaceutical research.

Conclusion

Martin De Hann's contributions to pharmaceutical chemistry exemplify the impact of innovation in addressing critical health challenges. His work not only advances scientific knowledge but also holds the potential to improve the quality of life for many patients.